BTAI BioXcel Therapeutics Inc.

-0.1  -1%
Previous Close 10.44
Open 10.58
Price To Book 5
Market Cap 161,984,393
Shares 15,665,802
Volume 18,012
Short Ratio
Av. Daily Volume 45,883

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 top-line data due 3Q 2019 with Phase 3 pivotal trial to commence 2H 2019.
Schizophrenia - Agitation
Phase 1/2 initial data due 2H 2019.
BXCL701 and Keytruda
Neuroendocrine Prostate Cancer (tNEPC)
Phase 1/2 initial data due 2H 2019.
Pancreatic cancer

Latest News

  1. BioXcel Therapeutics Added to Russell 3000® Index
  2. BioXcel Therapeutics to Participate in the BMO 2019 Prescriptions for Success Healthcare Conference
  3. BioXcel Therapeutics Completes Dosing Two Cohorts of Agitated Schizophrenia Patients with BXCL501 in a Phase 2 Efficacy Trial
  4. BioXcel Therapeutics CEO, Dr. Vimal Mehta to Participate in BIO International Convention Panel on Innovative Clinical Trial Designs
  5. BioXcel Therapeutics Announces FDA Clearance of IND Application for Triple Combination in Pancreatic Cancer and CTA Acceptance for Double Combination in Aggressive Form of Prostate Cancer (tNEPC) for Lead Immuno-Oncology Program, BXCL701
  6. BioXcel Therapeutics to Present at the Jefferies 2019 Global Healthcare Conference
  7. BioXcel Therapeutics, Inc. uses AI technology to develop drugs
  8. BioXcel Therapeutics Achieved Targeted Exposures of BXCL501 Designed For Non-Invasive Acute Treatment of Agitation in Neuropsychiatric Diseases
  9. BioXcel Therapeutics to Highlight Advances in the BXCL501 Program at 2019 Investor Event in New York City
  10. BioXcel Therapeutics to Present at the 2019 UBS Global Healthcare Conference
  11. BioXcel Therapeutics Reports First Quarter 2019 Results and Provides Business Update
  12. BioXcel Therapeutics Advances Process Development for BXCL501 Thin Film Formulation
  13. BioXcel Therapeutics to Host First Quarter 2019 Financial Results and Business Update
  14. Does BioXcel Therapeutics's (NASDAQ:BTAI) Share Price Gain of 46% Match Its Business Performance?
  15. BioXcel Therapeutics to Present at Upcoming Investor Conferences in April
  16. BioXcel Therapeutics Showcases Data on BXCL701 in Combination with OX40 Agonist in Late-breaking Poster Presentation at AACR Annual Meeting
  17. BioXcel Therapeutics Files Clinical Trial Application for the Development of BXCL701 and Pembrolizumab in Neuroendocrine Prostate Cancer (tNEPC)
  18. BioXcel Therapeutics to Present at 29th Annual Oppenheimer Healthcare Conference
  19. BioXcel Therapeutics Announces Late Breaking Data Presentation at AACR 2019 Annual Meeting
  20. BioXcel Therapeutics Reports Fourth Quarter and Full Year 2018 Quarterly Results and Provides Business Update